Could the key to better CAR-T therapy lie in the gut?

NCT ID NCT05725720

Ongoing Knowledge-focused Sponsor: University of Bologna Source: ClinicalTrials.gov ↗

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This study explores whether the types of bacteria living in a person's gut can influence how well CAR-T cell therapy works for diffuse large B-cell lymphoma. Researchers will track changes in the gut microbiome of 69 patients from before treatment up to 18 months afterward. The goal is to see if certain bacterial patterns are linked to better responses or fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gut microbiome analysis (no drug or treatment given)
What this could lead to: If certain gut bacteria are linked to better CAR-T responses, this could point toward ways to improve treatment outcomes by modifying the microbiome.
What could go wrong: This is an observational study, not a treatment trial. It may find no clear link between gut bacteria and CAR-T outcomes, or the findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIFFUSE LARGE B CELL LYMPHOMA

Contacts and locations

Show contact details

Locations

Institute Of Hematology "Seràgnoli"

Bologna, 40138, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.